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The treatment of acute ischemic stroke is dependent on timely recognition. After ensuring airway, 
respiratory and circulatory stability, NIHSS should be performed and urgent CT scan obtained. If no 
exclusions exist, recombinant tissue plasminogen activator (rtPA) should be administered as soon as 
possible. Select patients may be eligible for mechanical thrombectomy. Stroke patients should be 
admitted to a dedicated stroke service to determine stroke mechanism, manage risk factors, and initiate 
preventive therapies. 
 
 
INTRODUCTION 
 
Epidemiology 
800,000 strokes occur in the United States (US) 
each year with 80% being first time events (1). 
A large international study recently identified 
hypertension, lack of exercise and elevated 
serum lipids as the most significant risk factors 
for an acute stroke (2). Attention to these and 
other independent stroke predictors including 
diabetes mellitus, obesity, smoking and 
cardiovascular disease decreased stroke 
incidence in the last 30 years (3). Adoption of 
the Mediterranean diet alone can reduce first 
stroke events by 40% (4). The use of statins and 
antihypertensive medications correlates with a 
40% decrease rate of stroke in Medicare patients 
older than the age of 65 (5). Recurrent stroke 
rates dropped from 9% in the 1960s to 5% in the 
2000s with a projected rate of under 3% in the 
coming decade (6).  Despite these trends, stroke 
remains the second leading cause of death 
worldwide, the fifth leading cause of death in the 
US and a primary cause of long-term disability 
(1,7). 
Significant ethnic, gender and 
geographic stroke disparities exist. Although 
stroke is more common in men younger than 79 
years old than in women (8), the lifetime risk of 
stroke is higher in woman due to a longer life 
expectancy (9). Stroke symptoms are more 
common in blacks than whites, and in those with 
lower economic and educational status (10).  
Although stroke incidence declined among white 
Americans between 1990 and 2005, stroke 
incidence in blacks remained unchanged (11). 
Black and Mexican Americans also have a 
higher incidence of both young age stroke and 
stroke-related deaths than white Americans 
(1,12). Reflecting this ethnic disparity, stroke 
mortality is 20% higher in the Southeast stroke 
belt of the US (13). 
 
Pathophysiology 
More than 85% of strokes are ischemic with the 
remainder being hemorrhagic (1). The Trial of 
ORG 10172 in the Acute Stroke Treatment 
(TOAST) etiologic classification system divides 
ischemic strokes based on their etiology as 
follows: large-vessel atherosclerosis, 
cardioembolic source, small-vessel disease, 
other determined causes, and cryptogenic (14). 
A recent analysis of an acute ischemic stroke 
confirmed by diffusion-weighted imaging 
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(DWI) in a large Asian cohort utilizing TOAST 
classification found large-artery atherosclerosis 
to be the most common stroke subtype with the 
middle cerebral artery (MCA) territory most 
frequently affected (15). However, a non-Asian 
population determined cardioembolic stroke to 
be the most common subtype (16). In fact, atrial 
fibrillation, the prevalence of which is estimated 
to rise to 12 million in the US by 2030, 
independently increases stroke risk five-fold 
across all ages (17,18). 
Although stroke was once defined as the 
rapid development of disturbed cerebral function 
lasting at least 24 hours or leading to death (19), 
clinically “silent” strokes occur in 20% of 
healthy elderly patients (20), and one third of 
transient ischemic attacks result in an acute 
ischemic lesion on an MRI (21). The modern 
definition of stroke encompasses retinal, brain, 
or spinal cord ischemic cell death as defined by 
neuroimaging, neuropathology, or clinical 
examination (22).  
How quickly clinical symptoms of a 
cerebral ischemia emerge following a vascular 
occlusion depends on the rate at which cerebral 
autoregulation fails to perfuse collateral blood 
vessels (23). Cerebrovascular hemodynamic 
compromise is first met by a compensatory 
increase in cerebral blood volume in order to 
maintain constant cerebral blood flow (24). 
After cerebral vasodilation is maximized, blood 
oxygen extraction increases in an attempt to 
maintain tissue viability. However, as this 
autoregulatory process is overwhelmed, cerebral 
blood flow decreases resulting in tissue 
hypoperfusion and the formation of an ischemic 
penumbra—tissue that is no longer 
metabolically functional although still viable 
(25). If perfusion to the penumbra is not 
increased in a timely manner, an ischemic core 
of irreversible cell death results.  
 
Times is Brain 
It is estimated that two million neurons die for 
every minute that reperfusion is delayed (26). 
Intravenous thrombolysis via recombinant tissue 
plasminogen activator (rtPA; alteplase) within 
4.5 hours is safe and effective for many acute 
stroke patients (27-30). rtPA increases the 
likelihood of patient independence at three 
months and is now recommended equally for 
those younger and older than the age of 80 (27). 
However, its use is extremely time dependent 
(28). Every 30-minute delay in reperfusion by 
intra-arterial therapy decreases a good clinical 
outcome by 15% (29). The use of prehospital 
screening tools such as the Cincinnati 
Prehospital Stroke Scale or Los Angeles 
Prehospital Stroke Screen can readily identify 
stroke patients in the field. The Rapid Arterial 
Occlusion Evaluation (RACE) scale has also 
been shown to accurately identify patients with 
large arterial occlusion in the prehospital setting 
(30). The recent advent of formal telemedicine 
stroke guidelines (31) and the developing 
concept of mobile stroke units are addressing the 
profound problem of thrombolysis 
underutilization in acute stroke management 
(32). With the indisputable efficacy of 
endovascular thrombectomy (NNT = 2.6) and an 
intervention window of up to 7.3 hours, the 
opportunity to treat an acute ischemic stroke has 
never been greater (33,34).  
 
DIAGNOSIS  
 
Clinical Diagnosis 
A patient suspected of having an acute stroke 
should be treated emergently. After ensuring 
respiratory and hemodynamic stability, it is 
crucial to confirm the time the patient was last 
known to be well. Knowledge of the last known 
well will determine if the patient is within the 
time window for an acute intervention. Although 
a general screening assessment may be 
performed by the nursing staff, it is most 
important that the National Institute of Health 
Stroke Scale (NIHSS) be performed.  
NIHSS is a standardized assessment of 
level of consciousness, language, neglect/ 
extinction, visual fields, eye movements, facial 
symmetry, motor strength, sensation, and 
coordination as demonstrated in Table 1 (35). 
The NIHSS can be performed quickly by various 
healthcare providers, and the certification can be 
obtained online for minimal to no cost (36). 
Baseline NIHSS score <6 increases the 
likelihood of a good recovery while scores >16 
increase the likelihood of a severe disability or 
death (37). A future outcome at 3 months is best 
predicted by the baseline NIHSS score. A cut off 
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score of 13 on the NIHSS reliably predicts 
patient independence (38).  
 
 
 
Table 1.  National Institutes of Health Stroke Scale (NIHSS)  
1a. Level of Consciousness 0 = Alert; keenly responsive.  
1 = Not alert; but arousable by minor stimulation to 
obey, answer, or respond.  
2 = Not alert; requires repeated stimulation to attend, or 
is obtunded and requires strong or painful stimulation 
to make movements (not stereotyped). 3 = Responds 
only with reflex motor or autonomic effects or totally 
unresponsive, flaccid, and areflexic. 
1b. LOC Questions 0 = Answers both questions correctly.  
1 = Answers one question correctly.  
2 = Answers neither question correctly. 
1c. LOC Commands 0 = Performs both tasks correctly.  
1 = Performs one task correctly.  
2 = Performs neither task correctly. 
2. Best Gaze 0 = Normal.  
1 = Partial gaze palsy; gaze is abnormal in one or both 
eyes, but forced deviation or total gaze paresis is not 
present.  
2 = Forced deviation, or total gaze paresis not 
overcome by the oculocephalic maneuver. 
3. Visual 0 = No visual loss.  
1 = Partial hemianopia.  
2 = Complete hemianopia.  
3 = Bilateral hemianopia (blind including cortical 
blindness). 
4. Facial Palsy 0 = Normal symmetrical movements.  
1 = Minor paralysis (flattened nasolabial fold, 
asymmetry on smiling).  
2 = Partial paralysis (total or near-total paralysis of 
lower face).  
3 = Complete paralysis of one or both sides (absence of 
facial movement in the upper and lower face). 
5. Motor Arm 0 = No drift; limb holds 90 (or 45) degrees for full 10 
seconds.  
1 = Drift; limb holds 90 (or 45) degrees, but drifts 
down before full 10 seconds; does not hit bed or other 
support.  
2 = Some effort against gravity; limb cannot get to or 
maintain (if cued) 90 (or 45) degrees, drifts down to 
bed, but has some effort against gravity.  
3 = No effort against gravity; limb falls.  
4 = No movement. UN = Amputation or joint fusion, 
explain: _____________________  
5a. Left Arm  
5b. Right Arm 
6. Motor Leg 0 = No drift; leg holds 30-degree position for full 5 
seconds.  
1 = Drift; leg falls by the end of the 5-second period 
but does not hit bed.  
2 = Some effort against gravity; leg falls to bed by 5 
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seconds, but has some effort against gravity.  
3 = No effort against gravity; leg falls to bed 
immediately.  
4 = No movement. UN = Amputation or joint fusion, 
explain 
6a. Left Leg  
6b. Right Leg 
7. Limb Ataxia 0 = Absent.  
1 = Present in one limb.  
2 = Present in two limbs.  
UN = Amputation or joint fusion, explain 
8. Sensory 0 = Normal; no sensory loss.  
1 = Mild-to-moderate sensory loss; patient feels 
pinprick is less sharp or is dull on the affected side; or 
there is a loss of superficial pain with pinprick, but 
patient is aware of being touched.  
2 = Severe to total sensory loss; patient is not aware of 
being touched in the face, arm, and leg. 
9. Best Language 0 = No aphasia; normal.  
1 = Mild-to-moderate aphasia; some obvious loss of 
fluency or facility of comprehension, without 
significant limitation on ideas expressed or form of 
expression. Reduction of speech and/or 
comprehension, however, makes conversation about 
provided materials difficult or impossible. For 
example, in conversation about provided materials, 
examiner can identify picture or naming card content 
from patient’s response.  
2 = Severe aphasia; all communication is through 
fragmentary expression; great need for inference, 
questioning, and guessing by the listener. Range of 
information that can be exchanged is limited; listener 
carries burden of communication. Examiner cannot 
identify materials provided from patient response.  
3 = Mute, global aphasia; no usable speech or auditory 
comprehension. 
10. Dysarthria 0 = Normal.  
1 = Mild-to-moderate dysarthria; patient slurs at least 
some words and, at worst, can be understood with 
some difficulty.  
2 = Severe dysarthria; patient's speech is so slurred as 
to be unintelligible in the absence of or out of 
proportion to any dysphasia, or is mute/ anarthric. UN 
= Intubated or other physical barrier, explain 
11. Extinction and Inattention (formerly Neglect) 0 = No abnormality.  
1 = Visual, tactile, auditory, spatial, or personal 
inattention or extinction to bilateral simultaneous 
stimulation in one of the sensory modalities.  
2 = Profound hemi-inattention or extinction to more 
than one modality; does not recognize own hand or 
orients to only one side of space. 
 
The use of the NIHSS may help exclude 
stroke mimics (39). Several studies show that 
alternate diagnoses are found in 22 to 38% of 
suspected stroke cases (40-42). It is essential to 
distinguish stroke from notable mimics since 
rtPA administration not only exposes the patient 
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to unnecessary bleeding risk, but also costs more 
than $5400 on average (43). Notable stroke 
mimics include seizure, encephalopathy, 
syncope, migraine, sepsis, and toxic/ metabolic 
derangements (42). Compared to mimics, stroke 
is more likely if a patient has almost any focal 
neurological symptom, such as subjective hand 
weakness or objective hemiparesis (42). Stroke 
is also more common with a normal mental 
status, NIHSS 1b score of 0, admission to a 
cardiology service, atrial fibrillation at the time 
of onset or during hospitalization, history of 
prior stroke and obesity (40,42,44). In contrast, 
increased likelihood of a stroke mimic is seen 
with patients exhibiting objective confusion, 
known history of cognitive impairment, loss of 
consciousness, seizure at onset, retained ability 
to walk, and absence of lateralizing symptoms 
(40,42,44). In-hospital stroke alerts are typically 
activated by nurses or physicians when a 
patient's neurological status acutely changes 
from his/ her baseline. Nurses have been found 
to effectively identify in-hospital ischemic 
events and activate stroke alerts earlier (45). 
 
Neuroimaging for Diagnosis 
The non-contrast head CT scan remains the first-
line imaging study in suspected stroke patients 
(46). The National Institute of Neurological 
Disorders and Stroke (NINDS) Brain Attack 
algorithm for stroke assessment recommends CT 
within the first 25 minutes of symptom 
recognition (46). It is readily available, quick 
and allows for timely rtPA administration within 
the recommended 3 to 4.5 hour window when 
indicated. Identifying hemorrhage is a 
fundamental step prior to rtPA administration 
since the thrombolytic therapy may produce 
lethal bleeding in patients with intracranial 
hemorrhage. Such bleed is recognized on CT as 
a hyperdense signal (46). An early CT finding of 
ischemia is a loss of gray-white matter 
differentiation in the basal ganglia or the insular 
cortex (insular ribbon sign). This is a time 
dependent sign, more likely to be visible at 6 
hours after the stroke (46). CT also helps 
identify arterial occlusion with thrombus, which 
appears as a hyperdensity of the involved large 
artery (46,47). Typical locations are the M1 
segment of the middle cerebral artery 
(hyperdense MCA sign), within the Sylvian 
fissure, basilar artery (dot sign), the posterior 
cerebral artery, or the anterior cerebral artery 
(46,47). This early finding may predict early 
deterioration, worse prognosis and greater risk 
of hemorrhage following thrombolysis (46). 
Distal MCA branch occlusions have less 
swelling and mass effect compared to internal 
carotid artery (ICA) and proximal MCA 
occlusions with less serious clinical implications 
(48). 
Early hypoattenuation on a CT reflects 
severe hypoperfusion and possible irreversible 
damage (49). Detection of MCA territory 
hypodensity on hyperacute CT scans is a 
sensitive, prognostic, and reliable indicator of 
the amount of MCA territory undergoing 
infarction (50).VonKummar et al showed that 
less than 33% of the MCA territory parenchymal 
hypoattenuation predicted a good response to 
rtPA (51). Frank hypodensity within 6 hours or 
damage to one third or more of the MCA 
territory predicts poor prognosis and malignant 
edema (48). Other early parenchymal signs 
include attenuation of lentiform nucleus, 
hemispheric sulcal effacement and a midline 
shift (52). On the initial emergency CT scan, 
overt non-stroke processes must also be 
confidently excluded, such as tumor, subdural/ 
epidural hematoma, and a subarachnoid 
hemorrhage (46). Nevertheless, a non-contrast 
CT cannot definitively differentiate the ischemic 
core of irreversible cell death from the ischemic 
penumbra, which is at risk of infarction but 
salvageable by targeted reperfusion strategies. 
This crucial distinction is made by CT perfusion 
scanning with a sensitivity and specificity of 
more than 90% despite its limited spatial 
coverage (46,53). It is especially useful in wake-
up strokes or strokes with undetermined time of 
onset (54).  
CT angiography (CTA) is a rapid 
technique that allows extensive visualization of 
vessels from the aortic arch to the entire circle of 
Willis as well as the collaterals within seconds. 
It has 100% sensitivity and 82-100% specificity 
for identifying occlusions (46, 55-57).  It is also 
superior to a carotid ultrasound in differentiating 
high grade carotid stenosis from an occlusion 
(58). Due to its high accuracy and speed, CTA is 
highly valuable in the rapid triage of hyperacute 
stroke patients to intra-arterial thrombolytic 
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treatment (59). CTA is also beneficial in 
recognizing large non-stenotic plaques, more 
common in the ipsilateral carotids, which are 
implied in cryptogenic strokes (60). Multiphase 
CTA is an imaging tool that provides three time-
resolved images of pial arterial filling in the 
whole brain; it has excellent inter rater 
agreement, especially for anterior circulation 
occlusions (61,62). Multimodal CT evaluation 
improves detection rate and prediction of the 
final size of an infarction in comparison with 
unenhanced CT, CT angiography, and perfusion 
CT alone (63). The role of magnetic resonance 
imaging (MRI) in acute ischemic stroke is a 
topic of ongoing study. MRI can aid appropriate 
selection of patients who need endovascular 
therapy and decrease exposure to invasive 
procedures in inappropriate patients thus 
improving outcomes and patient safety (64). 
 
 
TREATMENT 
 
Currently the only USFDA approved medical 
therapy for an acute ischemic stroke within 3 
hours of last known normal is intravenous rtPA. 
The recommended dose is 0.9 mg per kg body 
weight with 10% given as an initial bolus. The 
NINDS rtPA stroke study demonstrated a 
benefit of intravenous rtPA therapy for patients 
with ischemic stroke compared to placebo 
regardless of the stroke subtype. As compared to 
placebo, patients treated with rtPA were at least 
30% more likely to have minimal or no 
disability at three months with no increase in 
mortality (65). Multiple trials have demonstrated 
a greater benefit when treatment is initiated 
within 3 hours of the onset of symptoms (66). 
Patients with NIHSS of 20 or more have an 
increased risk of a hemorrhagic transformation 
of the ischemia after rtPA (67). It is 
recommended that acute stroke patients be 
admitted to specialized, dedicated stroke units 
whenever possible as they are associated with a 
higher rate of timely administration of rtPA 
when compared to hospitals without stroke units 
(67). 
Intravenous rtPA administration 3 to 4.5 
hours after the onset of stroke symptoms is 
associated with a modest but significant 
improvement in the clinical outcome, without a 
higher rate of symptomatic intracranial 
hemorrhage than that reported among patients 
treated within 3 hours (65). Treating patients 
outside these times is associated with an increase 
of hemorrhagic complications and death (66). 
Additionally, the extended time window for 
rtPA (i.e., 3-4.5 hours from last known normal) 
has additional exclusion criteria. These include a 
prior history of stroke and concomitant diabetes, 
any PT/INR if history of anticoagulation use, 
NIHSS >25, and age > 80 years.  
rtPA has a clear benefit in treatment in 
elderly stroke patients, those with severe stroke, 
those with diabetes mellitus and hyperglycemia, 
and those with minor early ischemic changes 
evident on computed tomography (27). The most 
common exclusion found for rtPA is delay in 
presentation to medical attention (69-71). Others 
include recent intracranial surgery, significant 
head trauma and on-going GI/ GU bleeding (27). 
The table shows the typical inclusion and 
exclusion criteria used prior to rtPA 
administration (Table 2) (27). 
 
Table 2. Inclusion and exclusion criteria for rtPA within 3 hours from last known well following acute ischemic 
stroke 
 Inclusion criteria: 
 Diagnosis of ischemic stroke causing measurable neurological deficit  
 Onset of symptoms<3 hours before beginning treatment 
 Aged ≥18 years  
 Exclusion criteria: 
 Significant head trauma or prior stroke in previous 3 months  
 Symptoms suggest subarachnoid hemorrhage  
 Arterial puncture at noncompressible site in previous 7 days  
 History of previous intracranial hemorrhage  
 Intracranial neoplasm, arteriovenous malformation, or aneurysm  
 Recent intracranial or intraspinal surgery  
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 Elevated blood pressure (systolic >185 mm Hg or diastolic >110 mm Hg) 
 Active internal bleeding  
 Acute bleeding diathesis, including but not limited to  
 Platelet count<100 000/mm³ 
 Heparin received within 48 hours, resulting in abnormally elevated Aptt greater than the upper limit of 
normal  
 Current use of anticoagulant with INR >1.7 or PT >15 seconds 
 Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory 
tests (such as aPTT, INR, platelet count, and ECT; TT; or appropriate factor Xa activity assays)  
 Blood glucose concentration<50 mg/Dl (2.7 mmol/L) 
 CT demonstrates multilobar infarction (hypodensity>1/3 cerebral hemisphere) 
 Relative exclusion criteria:  
 Recent experience suggests that under some circumstances—with careful consideration and weighting of 
risk to benefit—patients may receive fibrinolytic therapy despite 1 or more relative contraindications. 
Consider risk to benefit of IV rtPA administration carefully if any of these relative contraindications are 
present:  
 Only minor or rapidly improving stroke symptoms (clearing spontaneously)  
 Pregnancy  
 Seizure at onset with postictal residual neurological impairments  
 Major surgery or serious trauma within previous 14 days  
 Recent gastrointestinal or urinary tract hemorrhage (within previous 21 days)  
 Recent acute myocardial infarction (within previous 3 months) 
 Notes: 
 The checklist includes some FDA-approved indications and contraindications for administration of IV rtPA 
for acute ischemic stroke. Recent guideline revisions have modified the original FDA-approved indications. 
A physician with expertise in acute stroke care may modify this list. 
 Onset time is defined as either the witnessed onset of symptoms or the time last known normal if symptom 
onset was not witnessed. 
 In patients without recent use of oral anticoagulants or heparin, treatment with IV rtPA can be initiated 
before availability of coagulation test results but should be discontinued if INR is >1.7 or PT is abnormally 
elevated by local laboratory standards. 
 In patients without history of thrombocytopenia, treatment with IV rtPA can be initiated before availability 
of platelet count but should be discontinued if platelet count is <100 000/mm³. 
 aPTT indicates activated partial thromboplastin time; CT, computed tomography; ECT, ecarin clotting time; 
FDA, Food and Drug Administration; INR, international normalized ratio; IV, intravenous; PT, partial 
thromboplastin time; rtPA, recombinant tissue plasminogen activator; and TT, thrombin time 
 
Some stroke patients may be eligible for 
mechanical embolectomy (72). Endovascular 
therapy with clot retrievers, revascularization 
devices, or endovascular rtPA administration 
have all shown to have better revascularization 
rates, outcomes and prognosis compared to IV 
rtPA alone (73). Studies have shown that 
endovascular thrombectomy is beneficial, 
especially in strokes of anterior circulation, in 
patients >80 years of age and may be useful in 
those not eligible for IV rtPA(33). Recent 
mechanical thrombectomy trials have shown 
improved functional outcomes in patients who 
received a combination of rtPA followed by 
mechanical thrombectomy (74-76). A meta-
analysis showed that endovascular 
thrombectomy with medical therapy resulted in 
better outcomes at 3 months than medical 
therapy alone in large vessel strokes. The benefit 
was insignificant when thrombectomy was 
performed 7.3 hours after the symptom onset 
(34).  
Decompressive hemicraniectomy may 
be necessary in patients with large ischemic 
stroke who develop malignant cerebral edema 
and decreased level of consciousness. It reduces 
mortality and is recommended in patients <60 
years of age with unilateral MCA occlusion who 
deteriorate within 48 hours despite medical 
therapy. While it improves survival, most 
patients continue to have permanent disabilities 
(48). 
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INPATIENT CONCERNS  
 
A limited number of hematologic, coagulation, 
and biochemistry tests are recommended during 
the initial emergency evaluation in patients with 
suspected ischemic stroke to identify systemic 
conditions that may mimic stroke, that cause 
stroke or that may influence therapeutic options. 
These tests include blood glucose, electrolytes, 
complete blood count with platelet count, 
prothrombin time, activated partial 
thromboplastin time, international normalized 
ratio, and renal function studies (39,77). A 
clinical cardiovascular examination, cardiac 
enzymes tests, and a 12-lead electrocardiogram 
(ECG) should be performed in all stroke patients 
(78). Abnormalities on the non-contrast head CT 
scan remains the first-line imaging study in 
suspected stroke patients due to its ubiquity and 
exquisite sensitivity for ruling out hemorrhagic 
strokes (46). On the initial CT scan, overt 
nonstroke processes, as previously discussed, 
must be excluded. Chest radiographs in patients 
with an acute stroke are not indicated in the 
absence of appropriate clinical indications with 
only 3.8% of all patients radiographed having 
alterations in management (79). Most patients 
with stroke do not need an examination of the 
cerebrospinal fluid except for an evaluation of a 
patient with a stroke that may be secondary to an 
infectious illness or a subarachnoid hemorrhage 
(39,77). 
 
Airway and Ventilation 
Prevention of an early aspiration and airway 
protection are essential aspects of inpatient 
stroke care. Cheyne-Stokes respiration is 
frequent in stroke patients. Supplemental oxygen 
is recommended if the patient is hypoxic with 
saturation <92% (39,80,81). Patients with 
decreased consciousness, absent corneal and 
light reflex, cardiomyopathy, and age >80 years 
have the greatest risk for poor airway protection 
(82-84). Patients with an MCA stroke who 
require mechanical ventilation have high 
mortality regardless of the cause of intubation. 
The survival is associated with incomplete MCA 
territory involvement and atherosclerosis origin 
(85). Endovascular studies have noticed that 
patients who require general anesthesia have 
worse functional outcomes at 90 days versus 
those who do not require general anesthesia as 
part of their acute care (86).  
 
Cardiac Monitoring 
The most common arrhythmia detected in the 
setting of a stroke is atrial fibrillation. 
Common ECG changes secondary to a stroke 
with left-sided neurological events include an 
ST-segment depression, QT dispersion, and a 
prolonged QT interval (87-89). Therefore, 
guidelines recommend patients with an acute 
ischemic stroke should have cardiac monitoring 
for at least the first 24 hours and treatment of 
any serious cardiac arrhythmias that arise. 
 
NEURO ICU MANAGEMENT  
 
Pressure Augmentation 
The ischemic penumbra is the collaterally 
perfused area surrounding the infarct in a setting 
of impaired autoregulation wherein the impaired 
blood flow is insufficient for normal neuronal 
function, but sufficient for cell viability (90). 
Elevated blood pressures following an ischemic 
stroke serve to preserve perfusion to the 
penumbra and this is the rationale behind 
pressure augmentation (91). Blood pressure is 
increased in a step wise manner using IV 
vasopressors and regular neurological 
examinations guide escalation end-points as well 
as weaning of augmentation (39,77,91). Multiple 
perfusion imaging studies have demonstrated 
that an elevation in blood pressure with 
phenylephrine partially restores perfusion to the 
penumbra. (90,92-95). Rordorf et al. showed 
that maintaining a mean systolic blood pressure 
of 156 mm Hg (range 120 to 190 mm Hg) 
proved clinically beneficial (94). Wityk et al. 
also demonstrated improvements in perfusion 
imaging by maintaining the systolic blood 
pressure 20-30% above baseline (96,97). 
Ischemia can be identified by changes in tissue 
metabolism and oxygenation by monitoring 
brain tissue oxygen tension and microdialysis 
(91). Continuous EEG monitoring is 
noninvasive and demonstrates higher prevalence 
of slower frequencies with decreased cerebral 
blood flow (91). Other treatment options include 
withdrawing previous antihypertensive therapy 
and augmenting intravenous fluids. Historically, 
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it has been thought that keeping the head of the 
bed as flat as possible might improve cerebral 
perfusion; however, this theory has been 
recently challenged (98). 
 
POST rtPA CARE 
 
Blood Pressure 
Blood pressure is found to be elevated in most 
patients on the day of admission and such early 
elevation is thought to be a physiological 
response to ischemia. Patients with preexisting 
hypertension with moderately elevated pressures 
may not require antihypertensive therapy as it 
can impair cerebral blood flow and lead to 
neurological deterioration (99). rtPA is given 
only if blood pressure is less than 185/110; it 
should be maintained at that level for the first 24 
hours after rtPA administration (39,77). For 
patients who do not receive rtPA, the American 
Heart Association/ American Stroke Association 
(AHA/ASA) guidelines recommend initially 
withholding antihypertensive treatment unless 
the blood pressure is greater than 220/120 
(39,77). 
 
Temperature 
Hyperthermia acts through several mechanisms 
to worsen cerebral ischemia, some of which 
include enhanced release of neurotransmitters, 
exaggerated oxygen radical production, and 
worsening of cytoskeletal proteolysis (100). A 
temperature greater than >37.9ᵒC within the first 
week after the stroke was an independent 
predictor of a poor outcome (101,102). 
Lowering an acutely elevated temperature 
greatly influences outcome and prognosis (103). 
Therefore, guidelines suggest that sources of 
fever should be treated, and antipyretic 
medications should be administered to lower the 
temperature in febrile stroke patients.  
 
Glucose 
There is a correlation between an admission 
glucose concentration, diabetes, and poor stroke 
outcomes, which may not be attributed to the 
stroke type or location. Increased mortality was 
evident in the hyperglycemic and diabetic 
groups (104). Hyperglycemia is associated with 
lactic acidosis and conversion of penumbral 
tissue to an infarction, greater final infarct size, 
and worse functional outcome (104). These 
correlations were independent of baseline stroke 
severity, lesion size, and diabetic status (105). 
Insulin therapy benefits transient focal ischemia 
(106). Serum glucose concentrations 140-180 
mg/dL should probably trigger administration of 
insulin (77). Persistent hyperglycemia, as 
measured by serial blood glucose levels, is 
indicative of infarct evolution and worse clinical 
outcome regardless of baseline stroke severity 
than an isolated measure of glucose on 
admission to hospital (107).  
 
Antiplatelet/ Anticoagulation 
Two large trials studying the effects of aspirin 
and heparin in an acute stroke, the Chinese 
Acute Stroke Trial (CAST) and the International 
Stroke Trial (IST), have shown that starting 
aspirin as early as possible prevents stroke 
recurrence (108,109). AHA/ ASA guidelines 
recommend a dose of 325 mg orally within 48 
hours of an acute stroke (39,77). The use of 
anticoagulation is not recommended in the acute 
setting because of the risk of hemorrhagic 
transformation (108,109,110,111). 
 
DVT Prophylaxis 
Incidence of deep-vein thrombosis (DVT) in 
stroke patients is comparable with that seen in 
patients undergoing a hip or knee replacement 
with multiple risk factors for DVT, like 
advanced age, low Barthel Index severity score, 
or hemiplegia (112). As pulmonary embolism is 
found to be responsible for approximately 10% 
of deaths following an acute stroke, the 
prevention of this complication is of crucial 
importance (39,77). Prospective trials have 
shown that early heparin treatment with low 
molecular weight heparin (LMWH) is effective 
in reducing DVT and pulmonary embolism in 
stroke patients (112,113). Current guidelines 
recommend subcutaneous LMWH for DVT 
prophylaxis (39,77). 
 
HOSPITAL GOALS  
 
Etiology Workup  
The etiology of a stroke is determined based on 
clinical features and various diagnostic tests. 
Cardiac imaging with echocardiography is 
invaluable in an acute diagnosis (114). If 
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echocardiography is unrevealing and no 
arrhythmias are detected on telemetry during 
hospitalization, extended outpatient rhythm 
monitoring should be considered (115). Rare 
causes of stroke include non-atherosclerotic 
vasculopathies, hypercoagulable states, or 
hematologic disorders (14). Hypercoagulable 
etiological workup is necessary in younger 
stroke patients (116-118). 
 
Secondary Prevention 
Secondary prevention focuses on preventing 
recurrence of cerebrovascular events. 
Hypertension is a major correctable risk factor 
for stroke. Treatment of hypertension has been 
shown to reduce the incidence of primary and 
secondary strokes (119). A reduction in diastolic 
BP of 5 mm Hg is associated with one third 
lower risk of stroke (120). There is a high risk of 
recurrence of transient ischemic attacks and 
minor ischemic strokes due to atherosclerotic 
intracranial arterial stenosis and lacunar strokes 
(121-123). Dual antiplatelets, like aspirin with 
clopidogrel, may be necessary in some patients 
(121-123). If no contradictions are present, 
ischemic stroke/ transient ischemic attack 
patients with atrial fibrillation are anticoagulated 
long-term with warfarin or a newer oral 
anticoagulant (124). Identification of an aortic 
atheroma may prompt therapy with aspirin, 
statins and/ or anticoagulation to prevent 
recurrent strokes (125,126). Using statins in 
such patients decreases the likelihood of a 
subsequent stroke (127). Patients with an 
ejection fraction of < 30% and a predicted 5 year 
survival tend to do better if anticoagulated (128). 
The timing for starting anticoagulation is 
individualized to each patient and is dependent 
on size of the ischemia, etiology of the ischemia, 
and other risk factors.  
 
Recovery 
Stroke patients have a high incidence of 
dysphagia ranging from 51 to 78% (129). All 
stroke patients require a bedside dysphagia 
screen (39,77). In case of ongoing aspiration, a 
percutaneous gastrostomy is recommended. 
Lastly, an evaluation by physical and 
occupational therapists is necessary for 
disposition for rehabilitation.  
 
Outcomes 
The modified Rankin Scale (mRS) is a valid 
measure of disability and defines 6 grades of 
disability as demonstrated in Table 3 (130). A 
scale of 0-2 indicates mild disability; a scale of 3 
indicates moderate disability; scores of 4 or 5 
indicate severe disability; and a score of 6 
denotes death (130,131). It is employed to assess 
recovery from stroke after rtPA. A score of 0 or 
1 at 3 month follow-up is considered a favorable 
outcome, whereas a score of 2-6 represents an 
unfavorable outcome (65). The scale is found to 
have satisfactory inter-rater agreement and is 
widely used as an outcome parameter in clinical 
trials of stroke treatments (130,133,134).  
 
CONCLUSION 
Successful treatment of acute ischemic stroke 
depends on rapid diagnosis and determination of 
rtPA/ endovascular intervention candidacy.  
 
 
Table 3. Modified Rankin Scale (mRs) 
Grade  
0 No symptoms at all  
1 No significant disability: despite symptoms, able to carry out all usual duties and activities 
2 Slight disability: unable to perform all previous activities but able to look after own affairs without 
assistance 
3 Moderate disability: requiring some help but able to walk without assistance 
4 Moderately severe disability: unable to walk without assistance and unable to attend to own bodily needs 
without assistance 
5 Severe disability: bedridden, incontinent and requiring constant nursing care and attention 
6 Death 
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